The Impact of SCIP in Cosmetic Products
Since January 2021, it is mandatory for companies who produce, assemble, import or distribute products containing SVHC (above 0.1% w/w) in the European Union market to notify ECHA using the SCIP database.

Substances of Concern in Products (SCIP) database

Established under the Waste Framework Directive (WFD), as amended by Directive (EU) 2018/851, SCIP is the database for information on Substances of Concern In articles as such or in complex objects (Products). An article is considered “an object which during production is given a special shape, surface or design which determines its function to a greater degree than its chemical composition”.

Substances that may have serious and often irreversible effects on human health and the environment can be identified as substances of very high concern (SVHCs). If a substance is identified as an SVHC, it will be added to the Candidate List for eventual inclusion in the Authorisation List, according with ECHA (European Chemicals Agency).

Since January 2021, if a company produces, assembles, imports or distributes products or articles in the EU market that contain SVHCs on ECHA’s candidate list, in concentrations above 0.1% weight by weight (w/w), it has to submit information on these articles to ECHA. This means that the company needs to notify these articles to the SCIP database. Retailers which only supply articles to consumers do not need to notify ECHA.

The main goal of SCIP is to ensure that the information on articles containing Candidate List substances is available throughout the lifecycle of products and materials, including at the waste stage. With SCIP there is an increased knowledge of hazardous chemicals that are present in articles and products. The SCIP database should contribute to the reduction of hazardous substances in waste and encourage the substitution of these substances with safer alternatives, contributing to a better circular economy.

The information included in the SCIP database is made publicly available, mainly to consumers and waste operators. Consumers become able to make more informed choices when buying the products and waste operators benefit from an improvement on waste management practices and the promotion of waste use as a resource.

Protection of sensitive information such as the links between actors in the same supply chain is guaranteed by ECHA.

Companies need to submit the following information to register articles in the SCIP database:

  • Identification of the article;
  • Name, concentration range and location of the Candidate List substance (SVHC) present in it;
  • Other information that allows its safe use (notably information to ensure the article is properly managed once it becomes waste).

The foreign user concept allows third parties to submit data on behalf of other company.

It is important to implement an internal SVHC tracking process of the articles, collecting REACH compliant certification from the suppliers and calculating SVCH concentration in order to detect the threshold of 0.1% w/w.


The cosmetic product itself (i.e. cream, lotion, oil, etc.) is not considered an article. However, its packaging (the bottle, jar, pump, cap, brush in masks, etc.) is considered an article and so it is within the scope of REACH regulation. This means that if the packaging contains SVHC (>0.1%) it is mandatory to notify it.

In sum, starting this year, if your company is a manufacturer, assembler, importer or distributor of articles/products containing SVHC (at concentrations above 0.1% w/w), a notification to the SCIP database must be made. This information will become publicly available so it is essential to properly follow and complete the notification process.

Not sure if your company or your articles/products are included in this obligation? We can help you! Feel free to contact us at


  1. Directive (EU) 2018/851 of the European Parliament and of the Council of 30 May 2018 amending Directive 2008/98/EC on waste. Available at:
  2. Detailed information requirements for the SCIP database. European Chemicals Agency (ECHA). September 2019.
  3. SCIP. European Chemicals Agency (ECHA). Available at:
  4. Candidate List of substances of very high concern for Authorisation. European Chemicals Agency (ECHA). Available at:


medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »